Actionable news
All posts from Actionable news
Actionable news in PTLA: Portola Pharmaceuticals, Inc.,

Portola's AndexXa effective in reversing Factor Xa-associated bleeding in late-stage study; shares ahead 6% premarket

Portola Pharmaceuticals (NASDAQ:PTLA) is up 6% premarket, albeit on only 1,355 shares, in response to it announcement of positive interim results from a Phase 3b/4 study, ANNEXA-4, assessing the Factor Xa inhibitor antidote AndexXa (andexanet alfa) in reversing acute major bleeding associated with the anticoagulant. The data were presented today at the European Society of Cardiology Congress in Rome.

A preliminary analysis on interim results from 67 patients (47 evaluated for efficacy) showed a 30-minute bolus of AndexXa rapidly and substantially reversed anti-Factor Xa activity and sustained the reversal when followed by a 120-minute infusion. The majority of patients (79%) achieved good...